Today, the FDA announced major (and long overdue!) changes to the Mifeprex® (medication abortion pill) label.
Food and Drug Administration Scientific Workshop on Labeling Lower-Dose Estrogen-Alone Products for Symptoms of Vulvar and Vaginal Atrophy
Food and Drug Administration Hormonal Contraception Public Workshop on Drug Interactions with Hormonal Contraceptives: Public Health and Drug Development Implications
More than 80 percent of prescriptions filled in the United States are for generic drugs. Women get these prescriptions with the assumption that the drugs they’ve been prescribed are safe and effective.
Statement of Coco Jervis, J.D., Program Director |
Food and Drug Administration Public Meeting on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products